Free Trial
→ One executive order. The biggest wealth transfer of your lifetime. (From Reagan Gold Group) (Ad)tc pixel
NASDAQ:RCKT

Rocket Pharmaceuticals Q3 2024 Earnings Report

Rocket Pharmaceuticals logo
$3.67 -0.19 (-4.92%)
Closing price 05/7/2026 04:00 PM Eastern
Extended Trading
$3.68 +0.00 (+0.14%)
As of 05:31 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Rocket Pharmaceuticals EPS Results

Actual EPS
-$0.71
Consensus EPS
-$0.78
Beat/Miss
Beat by +$0.07
One Year Ago EPS
N/A

Rocket Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Rocket Pharmaceuticals Announcement Details

Quarter
Q3 2024
Date
11/7/2024
Time
After Market Closes
Conference Call Date
Wednesday, November 6, 2024
Conference Call Time
6:00PM ET

Upcoming Earnings

Rocket Pharmaceuticals' Q2 2026 earnings is estimated for Thursday, May 14, 2026, based on past reporting schedules

Conference Call Resources

Powered by Quartr

Earnings Documents

Rocket Pharmaceuticals' Q3 2024 Press ReleasePress Release
(8-K)
Rocket Pharmaceuticals' Q3 2024 Quarterly reportQuarterly report
(10-Q)

Rocket Pharmaceuticals Earnings Headlines

Analysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT) and TriSalus Life Sciences (TLSI)
April 29, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/TLSI/pressreleases/1597094/analysts-offer-insights-on-healthcare-companies-rocket-pharmaceuticals-rckt-and-trisalus-life-sciences-tlsi/
Analysts Conflicted on These Healthcare Names: Rocket Pharmaceuticals (RCKT), Merit Medical Systems (MMSI) and Vaxcyte (PCVX)
April 16, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/PCVX/pressreleases/1339978/analysts-conflicted-on-these-healthcare-names-rocket-pharmaceuticals-rckt-merit-medical-systems-mmsi-and-vaxcyte-pcvx/
One executive order. The biggest wealth transfer of your lifetime.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.tc pixel
 |  Reagan Gold Group (Ad)
Rocket Pharmaceuticals, Inc. (RCKT) Discusses FDA Approval of KRESLADI Gene Therapy for Severe Leukocyte Adhesion Deficiency Type 1 Transcript
March 27, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4886599-rocket-pharmaceuticals-inc-rckt-discusses-fda-approval-of-kresladi-gene-therapy-for-severe
Rocket Pharma shares climb as FDA approves first therapy for deadly childhood disorder
March 27, 2026  |  reuters.comhttps://www.reuters.com/business/healthcare-pharmaceuticals/rocket-pharma-shares-climb-fda-approves-first-therapy-deadly-childhood-disorder-2026-03-27/
Rocket Pharmaceuticals Launches New $100M At-The-Market Program
March 10, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/rocket-pharmaceuticals-launches-new-100m-at-the-market-program?utm_source=marketbeat.com&utm_medium=referral
See More Rocket Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Rocket Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rocket Pharmaceuticals and other key companies, straight to your email.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals (NASDAQ:RCKT) is a clinical-stage biopharmaceutical company focused on developing gene therapies for rare, inherited pediatric diseases. The company employs a proprietary adeno-associated virus (AAV) and lentiviral vector platform to deliver functional copies of genes in patients with genetic deficiencies. Its programs target a spectrum of disorders, including Fanconi anemia, leukocyte adhesion deficiency type I and Danon disease, with the goal of delivering one-time treatments that address the underlying causes of disease rather than merely managing symptoms.

The company’s pipeline comprises multiple product candidates in various stages of development. Lead programs such as RP-L102 for Fanconi anemia and RP-L301 for leukocyte adhesion deficiency type I have advanced into clinical trials, where Rocket is evaluating safety and preliminary efficacy. Preclinical efforts include gene therapy candidates for Danon disease and other lysosomal storage disorders. Rocket leverages in-house manufacturing capabilities alongside strategic partnerships to support its clinical and potential commercial supply needs.

Founded in 2015 as a spin-out from academic research institutions, Rocket Pharmaceuticals established its headquarters in New York City. Since inception, the company has expanded its research and development infrastructure to include state-of-the-art manufacturing and clinical trial support facilities. Its management team draws upon expertise in gene therapy development, regulatory strategy and rare disease commercialization to guide programs from laboratory to the clinic.

Rocket Pharmaceuticals serves patient populations primarily in the United States and collaborates with international academic and clinical centers to advance global trial enrollment. The company’s efforts are underpinned by partnerships with nonprofit organizations and academic research groups dedicated to rare disease advocacy, reflecting a commitment to bringing transformative therapies to underserved communities worldwide.

View Rocket Pharmaceuticals Profile
Earnings Tools